Medical
Health
Therapy

Invitae

$17.43
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.18 (-1.02%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Invitae and other stocks, options, ETFs, and crypto commission-free!

About

Invitae Corp. engages in the provision of genetic information into mainstream medical practice. It includes comprehensive panels for hereditary conditions in cancer, cardiology, neurology, pediatric, and rare diseases. Read More The company was founded by Randal W. Scott and Sean E. George on January 13, 2010 and is headquartered in San Francisco, CA.

Employees
788
Headquarters
San Francisco, California
Founded
2010
Market Cap
1.56B
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.39M
High Today
$17.93
Low Today
$17.39
Open Price
$17.71
Volume
331.32K
52 Week High
$26.77
52 Week Low
$7.08

Collections

Medical
Health
Therapy
2015 IPO

News

Seeking AlphaMay 14

Bearish Outlook On Invitae

As we look more in biotech opportunities, The Coin Agora is going to cover all stocks that make up the ARKG ETF. The last quarterly earnings posted a loss of 47 cents per share and moved the candles away from a bullish pattern. Invitae has started to correct its massive price hike in the first months of 2019, which kept a trend going from a share value hike in 2018. Invitae (NVTA) finds itself on a downward trend after reversing from highs attained in its very bullish 2018 performance. This downtrend is ...

1,175
The Motley FoolMay 9

Invitae Delivers Strong Growth in First Quarter, Readies Investment Surge

The genetic testing space has been a source of incredible growth in recent years. Invitae (NYSE:NVTA) didn't depart from that trajectory in the first quarter of 2019. While year-over-year revenue growth of 47% was much lower than the triple-digit increases it enjoyed in 2018, that's to be expected as the numbers grow larger. More importantly, Invitae continued to deliver on multiple parts of its long-term strategy. Direct sales to patients increased. During the quarter, the company decreased its cost of go...

625
The Motley FoolMay 9

Were Invitae's Quarterly Results Really That Bad?

Using genomics to identify genetic risks and inform treatment decisions is revolutionizing healthcare, but disruption rarely happens in a straight line -- a fact that was reinforced by Invitae's (NYSE:NVTA) first-quarter financial results.

376

Earnings

-$0.78
-$0.65
-$0.53
-$0.40
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Expected Aug 6, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.